Evidence map›Paper›PMID 34585848›Full record

ArticleEMBO molecular medicine2021

A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis.

Qiong Pan, Gang Luo, Jiaquan Qu, Sheng Chen, Xiaoxun Zhang, Nan Zhao, Jingjing Ding, Hong Yang, Mingqiao Li, Ling Li and 13 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Genetic testing in liver diseases: Clinical applications.JHEP reports : innovation in hepatology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. The role ofFrontiers in pediatrics · 2025
    Article
  9. [Progress in the treatment of progressive familial intrahepatic cholestasis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Guidelines for the Management of Cholestatic Liver Diseases (2021).Journal of clinical and translational hepatology · 2022
    Article
  15. [Guidelines on the management of cholestasis liver diseases (2021)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Qiong PanCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID 0000-0003-1033-3098
Gang LuoCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Jiaquan QuCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID 0000-0002-0204-5646
Sheng ChenDepartment of Pediatrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Xiaoxun ZhangCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID 0000-0002-3892-7464
Nan ZhaoCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Jingjing DingCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Hong YangCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Mingqiao LiCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Ling LiCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Ying ChengCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Xuan LiCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Qiaoling XieCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Qiao LiCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Xueqian ZhouCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Huiling ZouDepartment of Pediatrics, Changsha Hospital for Maternal & Child Health Care, Changsha, China.
Shijun FanMedical Research Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Lingyun ZouBao'an Maternal and Child Health Hospital, Jinan University, Shenzhen, China.
Wei LiuInstitute of Immunology, Third Military Medical University (Army Medical University), Chongqing, China.
Guohong DengDepartment of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Shi-Ying CaiDepartment of Internal Medicine and Liver Center, Yale University School of Medicine, New Haven, CT, USA.
James L BoyerDepartment of Internal Medicine and Liver Center, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-8959-6036
Jin ChaiCholestatic Liver Diseases Center, Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID 0000-0002-8543-4566
Army Medical University · CNYale University · USChangsha Hospital for Maternal and Child Health Care · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Semaphorin 7A (SEMA7A) is a membrane-bound protein that involves axon growth and other biological processes. SEMA7A mutations are associated with vertebral fracture and Kallmann syndrome. Here, we report a case with a mutation in SEMA7A that displays familial cholestasis. WGS reveals a SEMA7A

Indexed as

CholestasisCholestasis, IntrahepaticSemaphorinsAnimalsAntigens, CDATP-Binding Cassette TransportersChromatography, LiquidFemaleHumansMiceMutationOrganic Anion Transporters, Sodium-DependentSymportersTandem Mass SpectrometryAntigens, CDATP-Binding Cassette TransportersOrganic Anion Transporters, Sodium-DependentSema7a protein, mouseSemaphorinssodium-bile acid cotransporterSymportersbile acidbile salt export pumpliver injuryprogressive familial intrahepatic cholestasissemaphorin 7A

Identifiers

PMID34585848
PMCPMC8573601
OpenAlexW3203070001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.